دورية أكاديمية
أعرض في EDS

Vaginal micronized progesterone on preventing luteinizing hormone untimely surge in ART cycles: A prospective proof-of-concept study.

التفاصيل البيبلوغرافية
العنوان: Vaginal micronized progesterone on preventing luteinizing hormone untimely surge in ART cycles: A prospective proof-of-concept study.
المؤلفون: Souza MDCB; Fertipraxis Centro de Reproducao Humana - Rio de Janeiro (RJ), Brazil., Antunes RA; Fertipraxis Centro de Reproducao Humana - Rio de Janeiro (RJ), Brazil., Souza MM; Fertipraxis Centro de Reproducao Humana - Rio de Janeiro (RJ), Brazil., Mancebo ACA; Fertipraxis Centro de Reproducao Humana - Rio de Janeiro (RJ), Brazil., Barbeitas AL; Fertipraxis Centro de Reproducao Humana - Rio de Janeiro (RJ), Brazil., Raupp VA; Fertipraxis Centro de Reproducao Humana - Rio de Janeiro (RJ), Brazil., Rebello DM; Fertipraxis Centro de Reproducao Humana - Rio de Janeiro (RJ), Brazil.
المصدر: JBRA assisted reproduction [JBRA Assist Reprod] 2024 Jun 14. Date of Electronic Publication: 2024 Jun 14.
Publication Model: Ahead of Print
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Brazilian Society of Assisted Reproduction Country of Publication: Brazil NLM ID: 101684552 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1518-0557 (Electronic) Linking ISSN: 15175693 NLM ISO Abbreviation: JBRA Assist Reprod Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Brasília/DF : Brazilian Society of Assisted Reproduction, [2014]-
مستخلص: Objective: A new approach to evaluate whether Progestin-Primed Ovarian Stimulation with micronized vaginal progesterone was as effective as using dydrogesterone in suppress LH pulse surge in young women under stimulation in an oocyte donor programme.
Methods: This prospective study included 21 patients aged 19 to 32 years-old stimulated with Elonva® 150, associated or not with Menopur® or Merional® (75 or 150IU) since the beginning of the cycle, plus HMG 150-225IU after the 8th day or just HMG 150-300IU per day. Patients were placed in a PPOS protocol with micronized vaginal progesterone (MVP) 200 mg (Gynpro® Exeltis or Junno Farmoquimica) every 12 hours or dydrogesterone (Duphaston® Abbott) 10 mg every 8 hours from the start of stimulation until the day after the GnRH trigger with Triptorelin 0.2 mg (Gonapeptyl daily®). The primary endpoint was the prevention of untimely LH surge, and secondarily the number of 16 mm follicles, retrieved oocytes and metafase II.
Results: Fourteen oocyte donor patients were prescribed MVP while seven others received dydrogesterone (DYG).The gonadotropin protocols included 04 with Corifollitropin alfa 150 plus HMG since the beginning and complemented after the 7th day, and 17 times of just HMG. There was no diferences in the number of follicles >10≤15mm, ≥16mm or number of metafase II oocytes. There was no untimely LH surge on both groups and no OHSS was developed after the agonist trigger.
Conclusions: Progestin-Primed Ovarian Stimulation with micronized vaginal progesterone seems to be a compelling choice for preventing premature ovulation without compromising oocyte quality in women undergoing ovarian stimulation.
فهرسة مساهمة: Keywords: LH surge; Vaginal micronized progesterone; oocyte donor program; progesterone primed cycles
تواريخ الأحداث: Date Created: 20240614 Latest Revision: 20240614
رمز التحديث: 20240615
DOI: 10.5935/1518-0557.20240045
PMID: 38875128
قاعدة البيانات: MEDLINE
الوصف
تدمد:1518-0557
DOI:10.5935/1518-0557.20240045